Last updated 2026-07-20
- Raised $6.4M Seed round, Jul 2021
- Raised $1.4M Series A led by PipelBiz, Jun 2023
- Raised $700k grant, Jul 2022
Total raised
$9.5M
Last: Undisclosed Round 2023-07
Stage
Seed
Founded
2020
Headcount
2
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences
About
Nano24 is a clinical-stage company founded in 2020, pioneering and commercializing CD24-enriched exosomes as a breakthrough therapy for hyperactivation of the immune system, specifically targeting cytokine storm-related diseases. The company's technology, EXO-CD24, was developed through years of applied and clinical research in Prof. Nadir Arber's and Dr. Shiran Shapira's lab. It aims to provide an efficient and safer alternative to steroids for various inflammatory conditions, including Acute Respiratory Distress Syndrome (ARDS), sepsis, and autoimmune disorders.
Funding history · 4 rounds · $9.5M total
2023-06
A Round
$1.4M
★ PipelBiz
2022-07
Grant
$700K
2021-07
Seed
$6.4M
2020-06
Pre-Seed
$1.0M
Headcount over time
From 3 (2021-04) to 3 (2026-01) · +0 (+0%) · 15 points · source: Finder history + radar grounding
Q&A
- What is Nano24's primary focus in the medical field?
- Nano24 focuses on developing the next generation of immunomodulators to address the cytokine storm, a severe complication of various pulmonary and systemic diseases. Their initial focus is on the ARDS (Acute Respiratory Distress Syndrome) market.
- What is the core technology behind Nano24's drug development?
- Nano24 utilizes CD24 as the drug and Exosomes as the carrier to develop EXO-CD24, an exosomal-based drug derived from genetically manipulated human embryonic cells. This technology aims to solve the cytokine storm.
- When was Nano24 established and by whom?
- Nano24 was established in June 2020 by Prof. Nadir Arber and Dr. Shiran Shapira, building on 25 years of their accumulated knowledge and experience.
- What was Nano24's most recent funding round?
- In July 2023, Nano24 secured a funding round with PipelBiz as a lead investor.
- What is the total amount of funding Nano24 has raised to date?
- Nano24 has raised a total of $9,500,000 USD.
- What is the status of Nano24's product development?
- Nano24's product, EXO-CD24, is in the clinical trial stage, having completed phases Ib+IIa and IIb (dose-finding study) with reported high success rates.
- Does Nano24 hold any patents?
- Yes, Nano24 holds at least one patent for its technology.
Team · 2
Prof. Nadir Arber
Founder · CMO, Founder
Dr. Shiran Shapira
Founder · CSO, Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenesMicroorganismsMoleculesCells
Target customers
Healthcare & Life SciencesLife SciencesHealthcare
Business model
B2C
Highlights
1 PatentsVerified
Tags
drug-developmentantibodiespharma-companiesimmunotherapytargetingbiopharmaceuticaltargeted-therapygeneticsimmunologypreventionnanotechnologybiotechnologydrug-discovery
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nano24med.com/ |
|---|---|
| linkedin.com/company/70961582 |
Identifiers & details
| Legal name | Nano24 Ltd. |
|---|---|
| Former names | OBCTD24 |
| Founded | 2020-6 |
| Employees (exact) | 2 |
Radar intelligence
Web history (Wayback)
| Domain | nano24med.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516204989 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2020-06-10 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2023 |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | חביב אבשלום 3 תל אביב - יפו |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-25 | עדכון הפרה |